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ABSTRACT 
Metal-on-metal (MOM) hip resurfacing has recently been a popular prosthesis choice for the 
treatment of symptomatic arthritis, but results in the release of cobalt and chromium ions into the 
circulation that can be associated with adverse clinical effects. The mechanism underlying these 
effects remains unclear. While chromosomal aneuploidy and translocations are associated with this 
exposure, the presence of subtle structural epigenetic modifications in patients with MOM joint-
replacements remains unexplored. Consequently, we analysed whole blood DNA methylation in 34 
OA patients with MOM hip resurfacing (MOM HR) compared to 34 OA patients with non-MOM 
total hip replacements (non-MOM THR), using the genome-wide Illumina HumanMethylation 450k 
BeadChip. No probes showed differential methylation significant at 5% false-discovery rate (FDR). 
We also tested association of probe methylation levels with blood chromium and cobalt levels 
directly; there were no significant associations at 5% FDR. )LQDOO\ZHXVHGWKHµepigenetic clock¶ 
to compare estimated to actual age at sample for all individuals. We found no significant difference 
between MOM HR and non-MOM THR, and no correlation of age acceleration with blood metal 
levels. Our results suggest the absence of large methylation differences systemically following 
metal exposure, however, larger sample sizes will be required to identify potential small effects. 
Any DNA methylation changes that may occur in the local periprosthetic tissues remain to be 
elucidated. This article is protected by copyright. All rights reserved 
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INTRODUCTION 
Metal-on-metal (MOM) hip replacement and resurfacing have been, until recently, popular 
treatments of choice for patients with painful arthritis1, with over 1.5 million devices inserted 
worldwide2; 3. Wear and corrosion occur at the bearing surfaces of MOM prostheses and at modular 
junctions of all hip prostheses4; 5. This causes the release of metallic wear debris into the local 
tissues and peripheral circulation, resulting in a systemic elevation of cobalt and chromium 
concentrations6; 7.  
The adverse effects of elevated levels of metal exposure have been highlighted by the high failure 
rates of MOM prostheses8; 9, and by case reports of cardiac, neurological and endocrine disorders10, 
resulting in their recent recall from many markets11. Several investigators have described the 
detrimental effects of metal exposure on survival and function of cell types including bone cells, 
monocytes, and macrophages in-vitro12-15. The mechanism by which metal debris exerts these 
effects is still unclear, although some investigators have studied changes in gene expression of 
candidate genes in cell and animal models16-18.  
Several studies have reported metal-induced changes in DNA methylation, alteration in gene 
expression and cell physiology in the setting of cancer19-21. In particular, chromium (Cr) induces 
oxidative stress, leads to gene expression changes associated with cell-to-matrix adhesion in cell 
lines, and affects the methylation of several cancer genes in cell lines20. Furthermore, cobalt (Co) 
exposure leads to chromosomal breaks and aberrations in mice, and to DNA damage in human cell 
lines, likely due to inhibition of DNA repair22. However, the effects of chronic metal exposure on 
the patient epigenome and cell function in the setting of joint replacement remain unexplored.  
 
Here, we tested whether DNA methylation levels of over 400,000 loci differ between whole blood 
samples from MOM hip resurfacing patients (MOM HR) and conventional total hip replacement 
using a non-MOM bearing (non-MOM THR). We also directly tested the association of methylation 
levels with circulating metal levels. 
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METHODS 
Participants and phenotypes 
Patients were recruited from the community between November 24th, 2009 and May 20th, 2010, and 
provided written informed consent prior to participation. All patients were recruited from the 
operating records of a single surgeon, and the study was approved by the National Research Ethics 
Service (South Yorkshire REC 09/H131/62, and South Central REC 10/H0606/20). All methods 
were performed in accordance with the relevant guidelines and regulations. 
Patients with MOM HR that present with a pathology due to elevated circulating metal 
concentrations, subsequently undergo a revision surgery that eventually reduces the concentrations 
of metal in circulation 23; 24. It is therefore the patient population with a well-functioning MOM hip 
replacement which have low-level chronic exposure to circulating metals, for whom the longer term 
outcomes are unclear. The exposure cohort in the study consisted of a metal exposure group of 35 
patients with a well-functioning MOM HR. These were individually matched for gender to a non-
exposure group consisting of patients who had a received non-MOM THR, and were of similar age 
and time-since-surgery (Table 1). Whole blood samples were collected from all patients and Co and 
Cr levels measured by inductively-coupled plasma-mass spectroscopy (ICP-MS), as described 
previously25 (Table 1). Undetectable levels of Cr and Co were imputed as half the lowest observed 
value for that phenotype. Smoking was measured as a binary variable, indicating whether an 
individual had ever smoked (self-reported). Occupational and other non-arthroplasty environmental 
metal exposure was measured as a self-reported binary variable. 
Co and Cr levels showed high correlation (r=0.95, p<10-10). As expected, Co and Cr metal levels 
were significantly higher in 34 exposed than in 34 non-exposed subjects who passed quality control 
(Wilcox p<10-9; Table 1).  
 
DNA extraction 
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Genomic DNA was isolated from the whole blood samples using the QIAamp DNA Blood Midi Kit 
4LDJHQ+LOGHQ*HUPDQ\DFFRUGLQJWRPDQXIDFWXUHU¶VSURWRFRO 
 
Methylation: Illumina 450k BeadChip assay 
The DNA samples were quantified using NanoDrop 2000 and A260/280 ratio was used to assess for 
the presence of protein contaminants. The DNA sample concentrations were then normalized to 
50ng/µl. Bisulfite conversion of DNA was done using the Zymo EZ-96 DNA Methylation Assay as 
per manufacturer¶s guidelines (Zymo Research Corp., Irvine, CA). The DNA methylation levels in 
the bisulfite converted DNA was measured using the Illumina Infinium HD Methylation Assay 
(Illumina Inc,, San Diego, CA)  DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVBriefly, bisulfite DNA 
was isothermally amplified (20-24h) and fragmented enzymatically. Subsequently, the DNA was 
precipitated using isopropanol, resuspended in a hybridisation buffer and dispensed onto Illumina 
Infinium HumanMethylation450k BeadChips (12 samples/chip) for hybridisation at 48 °C (16±20 
h) in the Illumina Hybridisation Oven. The unbound and non-specifically bound DNA fragments 
were washed away and a single nucleotide extension of the BeadChip bound fragments was 
performed to incorporate the fluorescent (ddNTP) labels. The entire protocol was automated using 
the Freedom Evos robot (Tecan). The BeadChips were imaged using an Illumina iScan.  
 
Methylation Data Processing 
Initial quality control of samples was performed using Illumina GenomeStudio software by 
comparing the sample probe signal intensities with inbuilt control probes. Subsequently, the probes 
were filtered using the ChAMP package in R26. The un-hybridized probes (detection p-value >0.01; 
n=2,265), probes mapping to the sex chromosomes or those containing common SNPs within 2 
base-pairs of the CpG site (based on minor allele frequency of over 5% in 1000 Genomes Project 
Consortium 2010 data) were excluded. Additionally, probes that were not represented by a 
minimum of 3 beads in 5% of samples (n=549) and those that cross-hybridise with multiple 
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genomic location were also excluded27. Following the filtering process, a total of 426,225 probes 
were taken forward for subsequent analysis. All individuals had probe failure rates below 1%. 
Normalisation procedures to correct for background differences, dye-bias and differences in the 
probe chemistries were conducted using the µDDVHQ¶ pre-processing method in the wateRmelon R 
package28.  
 
Estimation of cell composition 
Since methylation levels were assessed in whole blood, the heterogeneity in the cell type 
composition between patients could influence the results and needs to be accounted for29. Cell 
composition for each individual were estimated using the function µestimateCellCounts¶ in the R 
package minfi30. This function infers the proportions of CD8+ T-cells, CD4+ T-cells, B cells, 
natural killer (NK) cells, monocytes and granulocytes for each sample, based on DNA methylation 
signatures of different the cell types29. One MOM HR sample had cell type proportion estimates 
outside of 6 median absolute deviations from the median of all samples; this sample and the 
corresponding matched non-MOM THR sample were excluded from all further analyses. We 
checked that all remaining samples had cell-type composition estimates consistent with ranges 
observed in large-scale studies of individuals of similar age29. Thirty-four individuals with MOM 
HR and 34 individuals with non-MOM THR were taken forward for further analyses (Table 1). 
 
Sample clustering 
Previous studies investigating genome-wide DNA methylation in OA patients have reported 
clustering of samples based on the global similarities of their methylation patterns31; 32. The samples 
were assessed for clustering using an unsupervised hierarchical clustering algorithm that forms 
groups by successively merging samples based on the similarity of their methylation patterns. The 
analyses were performed by using the µhclust¶ function in R. We accounted for sample gender, age-
at-sample, time-since-operation, smoking, metal exposure due to other causes, such as via any 
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occupational metal exposure or via hobbies, and cell composition by using residuals from linear 
regression of beta-values on these covariates. To confirm the clustering results, we also carried out 
a principal component analysis (PCA) on the residuals of beta values as used in the clustering, 
DSSO\LQJWKHµSUFRPS¶ function in R.   
 
Analysis of Differentially-Methylated Probes (DMPs) 
After quality control, we analysed 426,225 CpG sites in 34 MOM HR and 34 non-MOM THR 
samples. To identify DMPs between the MOM and non-MOM samples, a logistic regression model 
for each CpG site was fitted using the CpGassoc R package33, adjusting for the covariates of 
gender, age-at-sample, time-since-surgery, smoking status, non-hip replacement metal exposure and 
cell composition. Similar association analyses were also performed for plasma Cr and blood Co 
levels: in each case, the Cr or Co level was log10-transformed, and a linear regression model was 
fitted with the same ten covariates as above. The analyses were also repeated with the first PC as an 
additional covariate. DMPs in a given analysis were defined as probes with a difference significant 
at 5% False Discovery Rate (FDR).  
 
Analysis of Methylation age 
Methylation age (DNAmAge) was analysed using the RQOLQHµ'1$0HWK\ODWLRQ$JH&DOFXODWRU¶
(https://dnamage.genetics.ucla.edu/, accessed 17/09/2015), with the pre-QC non-normalised data as 
recommended (https://labs.genetics.ucla.edu/horvath/dnamage/faq.htm, last accessed 11/02/2016). 
This method is based on methylation levels at 353 CpG sites that strongly correlate with 
chronological age of across several tissues34. Age acceleration was measured as residuals of 
DNAmAge regressed on age-at-sample, as recommended. Differences in age acceleration between 
MOM HR and non-MOM THR samples were analysed using the µwilcox.test¶ function in R, and 
correlation with circulating metal levels was tested using the µcor.test¶ function with 
PHWKRG ´VSHDUPDQ´ in R . 
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Statistical Analyses 
All analyses were performed in R version 3.1.2, with packages and functions as listed above.  
 
RESULTS 
Estimation of cell-type composition 
Since methylation levels were assessed in whole blood and thus could be influenced by cell type 
heterogeneity, we estimated the cell type composition of all samples35.There were no significant 
differences in estimated proportions of CD8+ T-cells, CD4+ T-cells, B cells, natural killer (NK) 
cells, monocytes, and granulocytes between MOM HR and non-MOM THR samples (Wilcoxon test 
p-value >0.17 for difference in each of the cell types; Figure 1). Nonetheless, we used the cell type 
composition estimates as covariates in further analyses. 
 
Sample clustering 
A sub-cluster of ten individuals (one MOM HR, nine non-MOM THR) was identified using 
hierarchical clustering, and confirmed by Principal Component Analysis (PCA) (Figure 2A-B). This 
clustering could be attributed to technical reasons as all ten samples were located on the same 
methylation BeadChip (each BeadChip contains 12 samples). Hence the first principal component 
was used in subsequent analyses to account for the clustering. 
 
Differentially-methylated probes (DMPs) 
The probes were tested for differential methylation between MOM HR and non-MOM THR 
samples, using gender, age at sample, time since surgery, smoking, metal exposure not due to MOM 
HR, estimated cell type proportions, and the first principal component as covariates. No probe was 
significantly associated at 5% FDR, with only 58 probes showing association at 25% FDR (Figure 
3A). When association of methylation levels with blood cobalt (Figure 3B) and chromium levels 
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(Figure 3C) was tested, no probe showed a significant association with either of the metal levels at 
5% FDR.  
 
Methylation age 
In the 68 individuals that passed QC, age estimated from methylation (DNAmAge) was strongly 
correlated with actual age at sample (r=0.89, p<10-10). The age acceleration measure (residuals from 
regression of DNAmAge on age-at-sample) did not differ significantly between exposed and non-
exposed cases (Wilcox p>0.7), and was not significantly correlated with plasma chromium or blood 
cobalt levels (p>0.9) (Figure 4).  
 
DISCUSSION 
Metal-on-metal hip resurfacing is known to increase circulating cobalt and chromium levels in 
blood, to reduce cell survival and function12; 13; 17; 18, increase prosthesis failure8; 9, and rarely, lead 
to systemic illness10. To explore one potential mechanism for detrimental effects, we investigated 
blood DNA methylation differences between 34 osteoarthritis (OA) patients with metal-on-metal 
hip resurfacing (MOM HR), and 34 OA patients with a conventional total hip replacement (non-
MOM THR). To our knowledge, this is the first epigenome-wide study comparing MOM HR to 
non-MOM THR. 
We did not find any significant methylation differences between MOM HR and non-MOM THR 
samples, nor any significant methylation associations with either blood cobalt or chromium 
concentrations.  Moreover, clustering and PCA analyses did not show a clear separation of MOM 
HR and non-MOM THR samples, which suggests the absence of widespread global methylation 
differences.  
We also estimated biological age of the samples as DNA methylation age, and used it to calculate 
age acceleration (residuals of the DNA methylation age regressed on actual age at sample). It has 
been shown that methylation data can be used to estimate the biological age of an individual34. The 
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actual age. Age acceleration is highly heritable34, significantly correlated with physical and 
cognitive fitness36, and predicts all-cause mortality later in life37. We did not find any difference in 
age acceleration with MOM HR exposure, and no significant correlation of age acceleration with 
circulating blood metal levels.  
The study was well-powered to detect large methylation effects (~100% power for differences over 
25%), and the results indicate that such large effects are absent38. The power for smaller effects 
dropped sharply (with <50% power to detect methylation differences of 20% at genome-wide 
significance level), so that much larger samples will be needed to clarify the presence and extent of 
small methylation changes. For example, an estimated sample of 500 cases, 500 controls would be 
required to achieve over 80% power to detect a 5% case/control difference38. 
In summary, our data suggest that systemic metal exposure at the level experienced by patients with 
well-functioning metal-on-metal prostheses does not associate with large-effect genomic DNA 
methylation differences in circulating cells when compared to age, sex, and time since surgery 
matched patients who had received a non-MOM bearing total hip replacement. The changes that 
may occur in the local tissues surrounding the joint which are likely to be exposed to much higher 
levels of metal debris have not been examined in this study. Additionally, our study did not include 
patients with extreme levels of metal exposure, and large samples will be needed to clarify the 
presence of more subtle methylation changes than examined here. 
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Figure 1. Cell-composition estimates. Violin plots of different cell-type (CD8+ T-cells, CD4+ T-
cells, natural killer (NK) cells, B-cells, monocytes and granulocytes) illustrating the distributions 
for non-MOM THR and MOM HR samples after quality control. The white point shows the median 
value. 
 
Figure 2. Sample clustering. A) A dendrogram depicting results of unsupervised clustering using 
WKHµKFOXVW¶ function in R shows a formation of a sub-cluster (purple box), B) which is confirmed 
using principal component analysis. Samples forming the sub-cluster are adjacent in the 
methylation plate and likely represent a technical issue.  
 
Figure 3. Quantile-quantile plots for association of probe methylation levels with either A) sample 
case/control status, B) cobalt levels, or C) chromium levels. The x axis is -log10 of the expected p-
values under the null hypothesis of no association, and the y axis is -log10 of the observed p-values. 
Red line represents equality between observed and expected values. The p-values were obtained 
IURP ORJLVWLF UHJUHVVLRQ XVLQJ WHQ FRYDULDWHV EODFN ZLWK D YHU\ KLJK LQIODWLRQ Ȝ YDOXHV LQVHW
suggesting potential confounding. Logistic regression with an additional co-variate of 1st principal 
component (PC, purple) to account for sub-clustering of samples (potentially due to technical 
confounding) shows reduced inflation. 
 
Figure 4. DNAmAge acceleration and A) cobalt or B) chromium levels in samples. The y-axis is 
the measure of age acceleration (residuals from regression of DNAmAge on age-at-sample), the x-
axis shows the cobalt or chromium levels (log10-transformed). There is no significant correlation of 
age acceleration with either cobalt or chromium levels (p>0.9). 
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Table 1 Patient characteristics and metal levels for patients with metal-on-metal hip resurfacing 
(MOM HR) and a non metal-on-metal total hip replacement (non-MOM THR). 
  MOM HR Non-MOM THR 
Gender Male 30 30 
Female 4 4 
Smoking 
(current or 
past) 
Yes 12 12 
No 22 22 
Non-TJR 
metal 
exposure 
Yes 4 12 
No 30 22 
Age at sample 
(years)  
Median 
(Range) 
59.7  
(49.2-75.7) 
59.75  
(47.5-75.3) 
Time since 
operation 
(years) 
Median 
(Range) 
9.75  
(4.9-12.1) 
8.75 
(1.8-15.9) 
 
   
Cobalt 
(µg/L) 
Median 
(Range) 
1.84 
(0.56-36.99) 
0.60  
(0.17-4.52) 
Chromium 
(µg/L) 
Median 
(Range) 
2.52 
(0.44-27.54) 
0.34 
(0.12-3.01) 
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Figure 2 
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